Sonidegib

Search with Google Search with Bing

Information
Drug Name
Sonidegib
Description
Entry(CIViC)
2
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
basal cell carcinoma SMO MUTATION SMO MUTATION B Predictive Supports Resistance Somatic 2 26546616 Detail
Brain Medulloblastoma PTCH1 MUTATION PTCH1 MUTATION B Predictive Supports Sensitivity/Response Somatic 4 24651015 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Study explored the response to the SMO inhibitor s... SMO SMO MUTATION SMO MUTATION Resitance or Non-Reponse true CIViC Evidence detail
133 sonic-hedghog driven medulloblastomas were seq... PTCH1 PTCH1 MUTATION PTCH1 MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT04066504 Active, not recruiting Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma March 11, 2019 November 1, 2025
NCT02129101 Completed Phase 1 Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies May 2014 October 25, 2019
NCT02086552 Completed Phase 2 Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma January 17, 2014 August 13, 2021
NCT03434262 Completed Phase 1 SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors March 5, 2018 May 24, 2024
NCT04007744 Recruiting Phase 1 Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors February 13, 2020 July 2024
NCT03534947 Recruiting Phase 2 A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma July 23, 2019 June 2024
NCT04806646 Recruiting Phase 2 Tailored Sonidegib Schedule After Complete Response in BCC January 12, 2021 January 12, 2026
NCT05463757 Recruiting Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study November 1, 2021 December 2024
NCT04402073 Recruiting Phase 2 Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma November 11, 2022 March 1, 2030
NCT05669339 Suspended Phase 1 AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma June 2024 April 2026
NCT02303041 Terminated Phase 2 Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma February 2015 June 2017